Janux Therapeutics (JANX) Receivables (2020 - 2026)

Janux Therapeutics (JANX) has reported Receivables for 7 consecutive years, with $42.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $42.5 million (changed N/A YoY), while the FY2025 annual figure was $6.4 million, changed N/A from the prior year.
• Receivables climbed to $42.5 million in Q1 2026 per JANX's latest filing, from $6.4 million in the prior quarter.
• Across five years, Receivables topped out at $42.5 million in Q1 2026 and bottomed at $500000.0 in Q3 2022.
• Historically, Receivables has averaged $9.8 million across 5 years, with a median of $4.4 million in 2024.
• On a YoY basis, Receivables climbed as much as 484.8% in 2024 and fell as far as 484.8% in 2024.
• Janux Therapeutics' Receivables stood at $500000.0 in 2022, then jumped by 332.2% to $2.2 million in 2023, then jumped by 457.89% to $12.1 million in 2024, then plunged by 46.68% to $6.4 million in 2025, then surged by 560.59% to $42.5 million in 2026.
• Business Quant data shows JANX's Receivables at $42.5 million in Q1 2026, $6.4 million in Q4 2025, and $12.1 million in Q2 2024.